TLDR:
- BYSI Stock Surges 5.28%: Plinabulin Shows Strong Survival Benefit in NSCLC
- BeyondSpring’s Plinabulin Data Boosts NSCLC Treatment Hope, Stock Gains 5.3
- Plinabulin’s Phase 3 Results Strengthen BYSI’s Case for Global NSCLC Approval
- BYSI Stock Jumps 5.28% After Promising NSCLC Trial Results at ESMO Asia
- BeyondSpring Shows Survival Benefit with Plinabulin in NSCLC, Stock Soars
BeyondSpring Inc. (BYSI) saw a notable increase in its stock price, surging by 5.28%, after announcing promising results from its Phase 3 DUBLIN-3 trial.
BeyondSpring Inc., BYSI
The trial evaluated the combination of Plinabulin and docetaxel against docetaxel alone for treating second- and third-line EGFR wild-type non-small cell lung cancer (NSCLC). These results, presented at ESMO Asia 2025, revealed a significant survival benefit for patients using the Plinabulin combination, boosting market confidence and increasing the company’s stock to $2.1150.
Strong Results from the DUBLIN-3 Trial’s Asian Subset
In the Phase 3 DUBLIN-3 trial, the combination of Plinabulin and docetaxel showed a median overall survival (OS) of 10.8 months, compared to 8.8 months with docetaxel alone. The combination’s survival benefi-t was statistically significant with a hazard ratio (HR) of 0.81, meeting the primary endpoint (p=0.0426). This result supports the potential of Plinabulin to improve survival rates for patients with EGFR wild-type NSCLC, signaling a breakthrough in treatment options for this challenging condition.
Further analysis of the non-squamous subgroup showed even more favorable results. For this group, the hazard ratio was 0.69, which translates to a three-month median OS benefit (p=0.0064). These findings reinforce the targeted mechanism of Plinabulin, highlighting its potential to improve survival, especially for patients whose disease biology aligns with the drug’s immune-modulating properties.
Plinabulin also demonstrated a clear safety advantage over docetaxel. The combination therapy significantly reduced the incidence of docetaxel-induced grade 4 neutropenia, with only 3.9% of patients affected compared to 26.5% in the docetaxel-only group (p<0.0001). This reduction in neutropenia allows for better chemotherapy tolerability, crucial for maintaining treatment effectiveness and patient quality of life.
Plinabulin’s Mechanism and Future Prospects
Plinabulin, a first-in-class immune-modulating agent, works by targeting dendritic-cell maturation and tumor vasculature. The drug has already shown durable anti-cancer benefits and good tolerability in over 700 patients across various clinical studies. The combination of Plinabulin and docetaxel offers a novel treatment approach, improving survival rates while reducing chemotherapy-induced side effects.
BeyondSpring’s management is confident that the promising data from the DUBLIN-3 trial will support Plinabulin’s global registration for NSCLC. The company plans to advance Plinabulin through a global Phase 3 confirmatory study, aiming to expand its use beyond the Asian market. This study will be a critical step toward positioning Plinabulin as a standard-of-care treatment for NSCLC, especially for patients with EGFR wild-type mutations.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
